GlassScriptPhysician profile
Ashley J Ransel
NPI 1619353174
$9,564.13
in general payments reported to CMS, 2019-2025
47 companies · $2,089 in 2025
The $2,089 reported for 2025 was more than what 91% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,046 · 2022: $1,916 · 2023: $1,717 · 2024: $1,796 · 2025: $2,089.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,592 · Education: $10.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,592.40 |
| Education | $10.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,107.00 | 2021-2025 | |
| Novo Nordisk INC | $1,056.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $852.62 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $797.82 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $741.53 | 2021-2025 | Repatha, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.51 | 2021-2025 | Jardiance, Ofev |
| Lilly USA, LLC | $417.34 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Exact Sciences Corporation | $318.27 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $306.52 | 2021-2024 | Xarelto |
| Abbott Laboratories | $292.10 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $272.49 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.79 | 2021-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $207.88 | 2023-2025 | Voquezna |
| Astellas Pharma US INC | $206.64 | 2021-2025 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $190.92 | 2022-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $187.57 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $159.88 | 2022 | |
| Sanofi Pasteur INC. | $151.51 | 2023-2025 | |
| Daiichi Sankyo INC. | $119.01 | 2021-2023 | Injectafer |
| Sumitomo Pharma America, INC. | $118.75 | 2023-2025 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $109.26 | 2024-2025 | Nuzyra |
| Medtronic, INC. | $106.47 | 2023-2025 | Inceptiv, Venaseal |
| Esperion Therapeutics, INC. | $105.39 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $99.36 | 2022-2025 | |
| Dexcom, INC. | $98.44 | 2022-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $77.66 | 2021 | |
| Merck Sharp & Dohme LLC | $76.51 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $74.89 | 2023-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.26 | 2025 | Caplyta |
| Shield Therapeutics INC | $62.21 | 2024-2025 | |
| Verona Pharma, INC. | $58.97 | 2025 | Ohtuvayre |
| Nestle Healthcare Nutrition INC. | $53.62 | 2021-2022 | |
| Stryker Corporation | $50.91 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit, Clottriever Bold Catheter |
| Acadia Pharmaceuticals INC | $48.18 | 2025 | Daybue |
| Supernus Pharmaceuticals, INC. | $46.16 | 2023-2024 | Qelbree, Qelbree |
| Mylan Specialty L.P. | $43.52 | 2024 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $37.89 | 2021-2025 | Camzyos |
| Biogen, INC. | $29.63 | 2021-2022 | |
| Ibsa Pharma INC. | $24.46 | 2025 | Licart, Flector, Tirosint |
| Apria Healthcare LLC | $17.12 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.67 | 2022 | |
| Opko Pharmaceuticals, LLC | $16.64 | 2021 | |
| Lundbeck LLC | $16.50 | 2023 | Rexulti |
| Antares Pharma, INC. | $16.10 | 2022 | |
| Sanofi-Aventis U.S. LLC | $16.06 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.43 | 2021 | |
| Eisai INC. | $11.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Ransel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.